BREAST CANCER CONNECT’s Post

Read the blog: https://ow.ly/YCiM50S31if EVERSANA's Value & Evidence team synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. This comprehensive systematic literature review aimed to shed light on the real-world effectiveness of treatments administered after 1L CDK4/6.. Explore their findings and understand the complexities of post-CDK4/6i therapies. #BreastCancer #Oncology Sarah Kane, Belal Howidi, Bao-Ngoc Nguyen, Joanna Bielecki and Imtiaz A. Samjoo

Understand how the Breast Cancer Index® test identifies patients with a low risk of late distant recurrence, helping to personalize extended endocrine therapy treatment decisions. Learn from our recent webinar to help avoid over- and under-treatment. Watch here: https://bit.ly/3zv9aPx

Read the blog: https://ow.ly/YCiM50S31if EVERSANA's Value & Evidence team synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. This comprehensive systematic literature review aimed to shed light on the real-world effectiveness of treatments administered after 1L CDK4/6.. Explore their findings and understand the complexities of post-CDK4/6i therapies. #BreastCancer #Oncology Sarah Kane, Belal Howidi, Bao-Ngoc Nguyen, Joanna Bielecki and Imtiaz Samjoo

Both 0, 1+, green and yellow are qualitative terms. It is impossible to tell the border between yellow and green through "eyeballing". Think about how many in-between images between 0 and 1+ (the difference is the brown staining). Pathologists are asked to find the border between 0 and 1+ every day, as only 1+ qualified a breast cancer patient for Enhertu, a $140K/year targeted therapy drug (022024)

Learn about colorectal cancer, its symptoms, and risk factors with Dr. Sneha Kommineni, Consultant in Medical Oncology. Gain insights into early detection methods and post-diagnosis measures. Early screening is crucial. Contact Aster RV Hospital for more information. #ColorectalCancerAwareness #EarlyDetectionSavesLives #MedicalOncology #HealthcareInsights #AsterRV #AsterBangalore #AsterHospitals

Learn from Rena Callahan, MD* and Katherine Cohen, NP* on how they partner to provide personalized care for their patients by using the Breast Cancer Index test® for extended endocrine therapy treatment decisions. Watch here: https://bit.ly/3zv9aPx

🔍 In a compelling interview with Citeline Commercial's Medtech Insight, CEO Mike Kujak reveals how Francis Medical’s #Vanquish system is on track to redefine prostate cancer treatment. Our innovative #WaterVaporTherapy technology promises to significantly enhance patient outcomes while minimizing or eliminating side effects, like urinary incontinence or erectile dysfunction, often experienced with traditional treatments. 📈 We're aiming to set a new benchmark in care! Explore the strategic advancements and potential impact of Vanquish 💦 on the future of oncology at https://lnkd.in/gJukM4Q6 #ProstateCancer #FocalTherapy #ErectileDysfunction #UrinaryIncontinence #TouchOnCancer #GentleOnPatients

OA/US balances the need for specificity and efficiency in breast cancer diagnostics. Diagnose with fewer procedures and delays. Simplify the diagnostic care pathway for your clinical staff. See all the benefits at https://lnkd.in/gjA5ju_i #BreastCancer #optoacoustic #ImagioImaging

Important data from the ADAPTcycle trial on early endocrine response in HR+/HER2- presented at #SABCS2023 by PD Dr. med. Oleg Gluz ! Endocrine Response Assessment will also be implementes in the ESMO guidelines beginning of 2024 as a simple and effective tool helping to make treatment decisions for patients with early breast cancer!

In this #PeerExchange, experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes. Learn more about the groundbreaking treatments here: https://bit.ly/3WdkGsj #BreastCancer